U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Dysplastic oral leukoplakia

MedGen UID:
585584
•Concept ID:
C0399474
•
Neoplastic Process
SNOMED CT: Dysplastic oral leukoplakia (235030009)

Professional guidelines

PubMed

Treatment outcome of dysplastic oral leukoplakia with carbon dioxide laser--emphasis on the factors affecting recurrence.
Yang SW, Tsai CN, Lee YS, Chen TA
J Oral Maxillofac Surg 2011 Jun;69(6):e78-87. Epub 2011 Mar 12 doi: 10.1016/j.joms.2010.11.029. PMID: 21398012

Recent clinical studies

Etiology

Continuous artificial intelligence-assisted DNA aneuploidy cytology for surveilling dysplastic oral leukoplakia treated by photodynamic therapy.
He MJ, Wang F, Zhang J, Tan YQ, Chen XJ, Zhou G, Lu R
Photodiagnosis Photodyn Ther 2023 Jun;42:103588. Epub 2023 Apr 29 doi: 10.1016/j.pdpdt.2023.103588. PMID: 37127242
Dysplastic oral leukoplakia is molecularly distinct from leukoplakia without dysplasia.
Farah CS, Fox SA
Oral Dis 2019 Oct;25(7):1715-1723. Epub 2019 Jul 26 doi: 10.1111/odi.13156. PMID: 31295760
Treatment outcome of dysplastic oral leukoplakia with carbon dioxide laser--emphasis on the factors affecting recurrence.
Yang SW, Tsai CN, Lee YS, Chen TA
J Oral Maxillofac Surg 2011 Jun;69(6):e78-87. Epub 2011 Mar 12 doi: 10.1016/j.joms.2010.11.029. PMID: 21398012
The influence of resection and aneuploidy on mortality in oral leukoplakia.
Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A
N Engl J Med 2004 Apr 1;350(14):1405-13. doi: 10.1056/NEJMoa033374. PMID: 15070790
Topical bleomycin for the treatment of dysplastic oral leukoplakia.
Epstein JB, Gorsky M, Wong FL, Millner A
Cancer 1998 Aug 15;83(4):629-34. doi: 10.1002/(sici)1097-0142(19980815)83:4<629::aid-cncr1>3.0.co;2-f. PMID: 9708924

Diagnosis

Continuous artificial intelligence-assisted DNA aneuploidy cytology for surveilling dysplastic oral leukoplakia treated by photodynamic therapy.
He MJ, Wang F, Zhang J, Tan YQ, Chen XJ, Zhou G, Lu R
Photodiagnosis Photodyn Ther 2023 Jun;42:103588. Epub 2023 Apr 29 doi: 10.1016/j.pdpdt.2023.103588. PMID: 37127242
Dysplastic oral leukoplakia is molecularly distinct from leukoplakia without dysplasia.
Farah CS, Fox SA
Oral Dis 2019 Oct;25(7):1715-1723. Epub 2019 Jul 26 doi: 10.1111/odi.13156. PMID: 31295760
The influence of resection and aneuploidy on mortality in oral leukoplakia.
Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A
N Engl J Med 2004 Apr 1;350(14):1405-13. doi: 10.1056/NEJMoa033374. PMID: 15070790
Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.
Beenken SW, Sellers MT, Huang P, Peters G, Krontiras H, Dixon P, Stockard C, Listinsky C, Grizzle WE
Head Neck 1999 Sep;21(6):566-73. doi: 10.1002/(sici)1097-0347(199909)21:6<566::aid-hed11>3.0.co;2-h. PMID: 10449674
Topical bleomycin for the treatment of dysplastic oral leukoplakia.
Epstein JB, Gorsky M, Wong FL, Millner A
Cancer 1998 Aug 15;83(4):629-34. doi: 10.1002/(sici)1097-0142(19980815)83:4<629::aid-cncr1>3.0.co;2-f. PMID: 9708924

Therapy

Continuous artificial intelligence-assisted DNA aneuploidy cytology for surveilling dysplastic oral leukoplakia treated by photodynamic therapy.
He MJ, Wang F, Zhang J, Tan YQ, Chen XJ, Zhou G, Lu R
Photodiagnosis Photodyn Ther 2023 Jun;42:103588. Epub 2023 Apr 29 doi: 10.1016/j.pdpdt.2023.103588. PMID: 37127242
In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia.
Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z, Gao N, Zhang YY, Chen QM
Clin Cancer Res 2009 Nov 1;15(21):6724-31. Epub 2009 Oct 27 doi: 10.1158/1078-0432.CCR-09-1296. PMID: 19861457
Transforming growth factor-alpha: a surrogate endpoint biomarker?
Beenken SW, Hockett R Jr, Grizzle W, Weiss HL, Pickens A, Perloff M, Malone WF, Bland KI
J Am Coll Surg 2002 Aug;195(2):149-58. doi: 10.1016/s1072-7515(02)01219-x. PMID: 12168960
Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.
Beenken SW, Sellers MT, Huang P, Peters G, Krontiras H, Dixon P, Stockard C, Listinsky C, Grizzle WE
Head Neck 1999 Sep;21(6):566-73. doi: 10.1002/(sici)1097-0347(199909)21:6<566::aid-hed11>3.0.co;2-h. PMID: 10449674
Topical bleomycin for the treatment of dysplastic oral leukoplakia.
Epstein JB, Gorsky M, Wong FL, Millner A
Cancer 1998 Aug 15;83(4):629-34. doi: 10.1002/(sici)1097-0142(19980815)83:4<629::aid-cncr1>3.0.co;2-f. PMID: 9708924

Prognosis

Continuous artificial intelligence-assisted DNA aneuploidy cytology for surveilling dysplastic oral leukoplakia treated by photodynamic therapy.
He MJ, Wang F, Zhang J, Tan YQ, Chen XJ, Zhou G, Lu R
Photodiagnosis Photodyn Ther 2023 Jun;42:103588. Epub 2023 Apr 29 doi: 10.1016/j.pdpdt.2023.103588. PMID: 37127242
Treatment outcome of dysplastic oral leukoplakia with carbon dioxide laser--emphasis on the factors affecting recurrence.
Yang SW, Tsai CN, Lee YS, Chen TA
J Oral Maxillofac Surg 2011 Jun;69(6):e78-87. Epub 2011 Mar 12 doi: 10.1016/j.joms.2010.11.029. PMID: 21398012
The influence of resection and aneuploidy on mortality in oral leukoplakia.
Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A
N Engl J Med 2004 Apr 1;350(14):1405-13. doi: 10.1056/NEJMoa033374. PMID: 15070790
Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.
Beenken SW, Sellers MT, Huang P, Peters G, Krontiras H, Dixon P, Stockard C, Listinsky C, Grizzle WE
Head Neck 1999 Sep;21(6):566-73. doi: 10.1002/(sici)1097-0347(199909)21:6<566::aid-hed11>3.0.co;2-h. PMID: 10449674
Topical bleomycin for the treatment of dysplastic oral leukoplakia.
Epstein JB, Gorsky M, Wong FL, Millner A
Cancer 1998 Aug 15;83(4):629-34. doi: 10.1002/(sici)1097-0142(19980815)83:4<629::aid-cncr1>3.0.co;2-f. PMID: 9708924

Clinical prediction guides

Postoperative recurrence as an associated factor of malignant transformation of oral dysplastic leukoplakia.
Yang SW, Wu CJ, Lee YS, Chen TA, Tsai CN
ORL J Otorhinolaryngol Relat Spec 2010;72(5):280-90. Epub 2010 Aug 25 doi: 10.1159/000318874. PMID: 20798565
In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia.
Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z, Gao N, Zhang YY, Chen QM
Clin Cancer Res 2009 Nov 1;15(21):6724-31. Epub 2009 Oct 27 doi: 10.1158/1078-0432.CCR-09-1296. PMID: 19861457
Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia.
Zhang S, Li Y, Li L, Zhang Y, Gao N, Zhang Z, Zhao H
J Oral Maxillofac Surg 2009 May;67(5):1074-82. doi: 10.1016/j.joms.2008.06.079. PMID: 19375021
Transforming growth factor-alpha: a surrogate endpoint biomarker?
Beenken SW, Hockett R Jr, Grizzle W, Weiss HL, Pickens A, Perloff M, Malone WF, Bland KI
J Am Coll Surg 2002 Aug;195(2):149-58. doi: 10.1016/s1072-7515(02)01219-x. PMID: 12168960

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...